Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at BioTrinity 2022: Catalysing Growth in the Life Sciences Industry

Page View:


BioTrinity 2022 is only a couple weeks away! Medicilon is excited to attend and exhibit at the conference. Our Vice President and Business Development team will be exhibiting at the conferenceWe are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!

Date: April 26-27, 2022

Location: England, United Kingdom

ABOUT BioTrinity 2022

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

BioTrinity 2022 will feature

A dedicated 'Scientific Track', featuring a focus on seven core therapy areas; Oncology, CNS, Microbiome, Inflammation, Rare Disease, Infectious Diseases, as well as AI & Data.

Oncology is the branch of medicine that deals with the study and treatment of cancer, including research into cancer causes, prevention, early detection, and new therapies. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body.

The main goal of oncology is to diagnose and treat cancer as early as possible while minimizing the impact of treatment on the patient's quality of life. Treatment options for cancer include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. In recent years, there has been significant progress in the development of new treatments for cancer, such as personalized medicine and immunotherapy.

With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. At present, CAR-T, TCR-T, CAR-NK, oncolytic virus, antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, etc.), siRNA, AAV and other immunotherapy models and methods are used for evaluating the efficacy of immunotherapy and empowering the research process of innovative therapies and protect health!

Diseases of the CNS include a wide range of neurological and psychiatric conditions, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, and brain tumors. Treatments for CNS disorders may include medications, therapy, and surgery.

Research in CNS is a rapidly growing field, with discoveries and treatments being developed all the time, such as stem cells, gene therapy, and neuro-regeneration.

A relatively clinically reproducible and controllable cerebral ischemia model is essential for systematically studying the pathophysiology of cerebral ischemia and observing the therapeutic effect of drugs. According to the anatomical characteristics of cerebral vessels, cerebral ischemia models can usually be divided into global and partial cerebral ischemia, which can be divided into temporary and permanent ischemia. Because the anatomy of rat brain vessels and neurons are similar to those of higher animals, the reproducibility is good, the price is low, and because the brain tissue is small, it is convenient for biochemical detection after freezing. Therefore, in recent years, rats are often used to prepare models of cerebral ischemia.

Medicilon has MCAO models of rats and mice with stable lesions, high success rate, and high survival rate, which can carry out a reliable and effective evaluation of dose-effect and time-effect relationship, drug efficacy evaluation of transient cerebral ischemia, and permanent cerebral ischemia, According to the requirements of the STAIR technical guidelines, a variety of pharmacodynamic core index inspections are completed. Rodents with particular diseases can be modeled, and activity evaluations can be completed according to customized requirements.

The microbiome collects all the microorganisms (such as bacteria, viruses, fungi, and archaea) that live on and inside the human body. These microorganisms are found in various body sites, including the gut, skin, mouth, and respiratory tract.

Recent research has shown that the microbiome is closely connected to various diseases and health conditions, such as obesity, diabetes, cancer, autoimmune disorders, and mental health. The study of the microbiome is a rapidly growing field, and researchers are working to understand how the microbiome affects human health and how to manipulate it to improve health.

The gut microbiome is the most well-studied and is known to play a critical role in maintaining human health by influencing digestion, metabolism, immunity, and overall well-being.

The main mechanisms of microbial pathogenicity are:

(1)The structural substances of microorganisms stimulate the immune system of the human body and trigger pathogenic reactions;

(2)Certain substances secreted by microorganisms stimulate the immune response to cause disease;

(3)Microorganisms secrete certain pathogenic substances, which participate in and cause metabolic disorders in the human body;

(4)Microorganisms directly enter target cells and cause disease.

The understanding of the microbiome is still on its way, and it is expected that in the next few years, it will provide new insight into the causes of many diseases and new treatments and therapies that harness the power of the microbiome to improve health.

Inflammation, the body's natural response to injury, infection, or other forms of damage, can be classified as acute or chronic. Acute inflammation is a normal and healthy response to injury or disease and typically lasts for a short time. Chronic inflammation is a prolonged state that can last for months or even years. It is associated with various conditions, including cancer, heart disease, diabetes, and autoimmune disorders.

As the pathogenesis of inflammatory and immunological diseases is still being determined, only some effective therapeutic drugs are available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Medicilon Preclinical Pharmacodynamics Department has Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

A second 'life sciences business' focused presentation track, that will feature discussions and keynotes addressing topics from finance and investment, regulatory, government strategy and tax.

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance.

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D

Innovative Drug R&D Services

Antibody-Drug Conjugate(ADC) R&D project

PROTAC Drug Discovery Research Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

#drugdiscovery #BioTrinity #AI

Relevant newsRelevant news